Frank Hoentjen

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

Yukihide Momozawa, Julia Dmitrieva, Emilie Théâtre et al. · Nature Communications · 2018 · 252 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Reduction of Colitis by Prebiotics in HLA-B27 Transgenic Rats Is Associated with Microflora Changes and Immunomodulation

Frank Hoentjen, Gjalt W. Welling, Hermie J. M. Harmsen et al. · Inflammatory Bowel Diseases · 2005 · 216 citations

Life Sciences, Immunology, Microbiology +17

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

Vince Biemans, Andrea E. van der Meulen‐de Jong, C. Janneke van der Woude et al. · Journal of Crohn s and Colitis · 2019 · 184 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells

Frank Hoentjen, R. Balfour Sartor, Michitaka Ozaki et al. · Blood · 2004 · 143 citations · Full text

Life Sciences, Immunology, Molecular Biology +16